Xeris Biopharma Holdings, Inc. announced record total revenue of $71.5 million for the second quarter ended June 30, 2025, marking a 49% increase year-over-year. Product revenue also saw substantial growth, rising 45.6% year-over-year to $67.708 million, driven by increased patient demand across all three commercial products. Recorlev led this growth with a 135.7% year-over-year increase to $31.444 million.
The company reported a significant improvement in its financial performance, with net loss narrowing to $1.9 million, or ($0.01) per share, an 87% improvement compared to the prior year period. Adjusted EBITDA for the second quarter reached a positive $12.5 million, representing a $12.9 million improvement year-over-year, demonstrating strong operational efficiency.
Building on this momentum, Xeris raised its full-year 2025 total revenue guidance to a range of $280 million to $290 million, up from the previous range of $260 million to $275 million. This upward revision reflects confidence in continued patient demand and the company's ability to drive accelerated growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.